CRCA vs. UPRO
CRCA (ProShares Ultra CRCL) and UPRO (ProShares UltraPro S&P 500) are both Leveraged Equities funds from ProShares. CRCA is actively managed, while UPRO is passively managed. At a 0.44 correlation, their price movements are largely independent. CRCA charges 0.95%/yr vs 0.89%/yr for UPRO.
Performance
CRCA vs. UPRO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CRCA achieves a -25.37% return, which is significantly lower than UPRO's 27.90% return.
CRCA
- 1D
- -20.86%
- 1M
- -48.25%
- YTD
- -25.37%
- 6M
- -39.99%
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
UPRO
- 1D
- -2.09%
- 1M
- 14.64%
- YTD
- 27.90%
- 6M
- 26.67%
- 1Y
- 80.84%
- 3Y*
- 52.58%
- 5Y*
- 23.13%
- 10Y*
- 30.09%
CRCA vs. UPRO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | |
|---|---|---|
CRCA ProShares Ultra CRCL | -25.37% | -81.81% |
UPRO ProShares UltraPro S&P 500 | 27.90% | 20.41% |
Correlation
The correlation between CRCA and UPRO is 0.44, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (All Time) Calculated using the full available price history since Aug 8, 2025 | 0.44 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CRCA vs. UPRO — Risk / Return Rank
CRCA
UPRO
CRCA vs. UPRO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra CRCL (CRCA) and ProShares UltraPro S&P 500 (UPRO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Loading charts...
Sharpe Ratios by Period
| CRCA | UPRO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | — | 2.30 | — |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.46 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.56 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.47 | 0.65 | -1.12 |
Drawdowns
CRCA vs. UPRO - Drawdown Comparison
The maximum CRCA drawdown since its inception was -94.02%, which is greater than UPRO's maximum drawdown of -76.82%. Use the drawdown chart below to compare losses from any high point for CRCA and UPRO.
Loading charts...
Drawdown Indicators
| CRCA | UPRO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.02% | -76.82% | -17.20% |
Max Drawdown (1Y)Largest decline over 1 year | — | -26.78% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -48.87% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -63.94% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -76.82% | — |
Current DrawdownCurrent decline from peak | -87.98% | -2.09% | -85.89% |
Average DrawdownAverage peak-to-trough decline | -69.26% | -14.42% | -54.84% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 6.33% | — |
Volatility
CRCA vs. UPRO - Volatility Comparison
Loading charts...
Volatility by Period
| CRCA | UPRO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | — | 8.45% | — |
Volatility (6M)Calculated over the trailing 6-month period | — | 26.60% | — |
Volatility (1Y)Calculated over the trailing 1-year period | 196.79% | 35.35% | +161.44% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 196.79% | 50.32% | +146.47% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 196.79% | 53.74% | +143.05% |
CRCA vs. UPRO - Expense Ratio Comparison
CRCA has a 0.95% expense ratio, which is higher than UPRO's 0.89% expense ratio.
Dividends
CRCA vs. UPRO - Dividend Comparison
CRCA's dividend yield for the trailing twelve months is around 2.32%, more than UPRO's 0.68% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CRCA ProShares Ultra CRCL | 2.32% | 1.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
UPRO ProShares UltraPro S&P 500 | 0.68% | 0.84% | 0.93% | 0.74% | 0.52% | 0.06% | 0.11% | 0.41% | 0.63% | 0.00% | 0.12% | 0.34% |
Frequently Asked Questions
CRCA and UPRO have a correlation of 0.44, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, UPRO is cheaper at 0.89% per year. The better choice depends on whether you care most about return, fees, risk, or income.
UPRO is cheaper with a 0.89% expense ratio, compared with 0.95% for CRCA.
CRCA has the higher dividend yield at 2.32%, compared with 0.68% for UPRO.
Their fees differ too: 0.95% for CRCA and 0.89% for UPRO.
Find the right allocation for CRCA and UPRO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer